Labeling Updates For Old Drugs Could Be Faster Under Streamlining Proposal
Executive Summary
Stakeholder group's proposed pilot program to correct outdated drug labeling calls for US FDA to identify older products needing updates and contract out for evidence reviews, but agency and generic drug industry raise concerns about complexity, resources and product liability.
You may also be interested in...
Genentech’s Xeloda Is First Label Updated Under OCE’s ‘Project Renewal’
Capecitabine’s existing indications were revised and new indications added, reflecting uses that long have been considered standard of care; however, the cancer drug's label had been frozen in time since the approval of generics.
Senate Bill Would Prevent Safety Label Carve-Outs From Delaying Approvals
Updated drug pricing bill would allow US FDA to approve generics even if innovator safety information is protected by exclusivity.
Cancer Drugs: US FDA Looks Outside For Help On Generic Labeling Updates
Under the Oncology Center of Excellence’s Project Renewal, agency has contracted with consulting firm Deloitte to establish subject matter expert research teams that will review published literature on off-patent drugs and suggest labeling updates.